Ancora Biotech
Palo Alto
About Ancora Biotech
Developer of antibody biotherapeutics drugs intended to develop a treatment for several life-threatening diseases. The company focuses on clinical development support for the treatment of B cell cancers, inflammatory and metabolic disorders, and chronic hepatitis B infections, enabling healthcare workers to treat patients with various life-threatening diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $60.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2022)
- Website: ancorabiotech.com
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/ancora-biotech-127463 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.